Percutaneous implantation of the self-expandable corevalve for high risk patients with severe aortic valve stenosis: Early Israeli experience

Israel Medical Association Journal

Volumn 12, Issue 8, 2010, Pages 468-471

  Danenberg, Haim ^a   Finkelstein, Ariel ^b   Kornowski, Ran ^c   Segev, Amit ^d   Dvir, Danny ^c   Gilon, Dan ^a   Keren, Gad ^b   Sagie, Alex ^c   Feinberg, Micha ^d   Schwammenthal, Ehud ^d   Banai, Shmuel ^b   Lotan, Chaim ^a   Guetta, Victor ^d  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

Aortic replacement; Aortic stenosis; CoreValve

Indexed keywords

AGED; AORTA VALVE REGURGITATION; AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; ARTICLE; ARTIFICIAL HEART PACEMAKER; BALLOON DILATATION; BLOOD VESSEL OCCLUSION; BLOOD VESSEL PERFORATION; CLINICAL EFFECTIVENESS; COMORBIDITY; COMPLETE HEART BLOCK; DISEASE SEVERITY; FEMALE; FEMORAL ARTERY; FUNCTIONAL STATUS; HIGH RISK PATIENT; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; SUBCLAVIAN ARTERY; SURGICAL RISK; TRANSCATHETER AORTA VALVE REPLACEMENT;

AGED, 80 AND OVER; AORTIC VALVE STENOSIS; BIOPROSTHESIS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HEART VALVES; HUMANS; ISRAEL; MALE; PROSTHESIS DESIGN; RISK; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77957680647     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Varadarajan P, Kapoor N, Bansal RC, Pai RG. Clinical profile and natural history of 453 nonsurgically managed patients with severe aortic stenosis. Ann Thorac Surg 2006; 82(6): 2111-15.
2. Charlson E, Legedza AT, Hamel MB. Decision-making and outcomes in severe symptomatic aortic stenosis. J Heart Valve Dis 2006; 15(3): 312-21.
3. Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003; 24(13): 1231-43.
4. Pellikka PA, Sarano ME, Nishimura RA, et al. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation 2005; 111(24): 3290-5.
5. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation 2002; 106(24): 3006-8.
6. Zajarias A, Cribier AG. Outcomes and safety of percutaneous aortic valve replacement. J Am Coll Cardiol 2009; 53(20): 1829-36.
7. Grube E, Schuler G, Buellesfeld L, et al. Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome. J Am Coll Cardiol 2007; 50(1): 69-76.
8. Laborde J. Transcatheter aortic valve implantation with the CoreValve Revalving system. Presented at the 2008 TCT meeting, Washington DC, USA.
9. Piazza N, Grube E, Gerckens U, et al. Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. Eurointervention 2008; 4(2): 242-9.
10. Walther T, Falk V, Kempfert J, et al. Transapical minimally invasive aortic valve implantation; the initial 50 patients. Eur J Cardiothorac Surg 2008; 33(6): 983-8.
11. Webb JG, Altwegg L, Boone RH, et al. Transcatheter aortic valve implantation: impact on clinical and valve-related outcomes. Circulation 2009; 119(23): 3009-16.
12. Jilaihawi H, Chin D, Vasa-Nicotera M, et al. Predictors for permanent pacemaker requirement after transcatheter aortic valve implantation with the CoreValve bioprosthesis. Am Heart J 2009; 157(5): 860-6.